Preferred Name |
Niraparib |
|
Synonyms |
|
|
Definitions |
An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C80059 |
|
CAS_Registry |
1038915-60-4 |
|
code |
C80059 |
|
Contributing_Source |
CTRP FDA |
|
definition |
An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks. |
|
Display_Name |
Niraparib |
|
FDA_UNII_Code |
HMC2H89N35 |
|
Has_Salt_Form | ||
Has_Target | ||
in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
Is_Value_For_GDC_Property | ||
label |
Niraparib |
|
Legacy Concept Name |
PARP_Inhibitor_MK4827 |
|
Maps_To |
Niraparib |
|
NCI_Drug_Dictionary_ID |
615263 |
|
PDQ_Closed_Trial_Search_ID |
615263 |
|
PDQ_Open_Trial_Search_ID |
615263 |
|
Preferred_Name |
Niraparib |
|
prefixIRI |
NCIT:C80059 |
|
prefLabel |
Niraparib |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C2744440 |
|
subClassOf |